CYB561

Across TCGA pan-cancer cohorts, CYB561 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYB561 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CYB561 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CYB561 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

GBM, UCEC, and LUAD are the cancer types where CYB561 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.548	0.217	.001	23	view →
UCEC	DFS	Median	All	0.947	0.760	.004	6	view →
LUAD	DFS	Quartile	III,IV	0.132	0.565	.038	3	view →
HNSC	DFS	Median	III,IV	1.000	0.941	.047	1	view →
PDAC	DFS	Median	III,IV	0.600	0.785	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYB561–GBM (DFS)

Open the GBM breakdown →